Learn how Pfizer’s focus on immunotherapy aims to help people with multiple myeloma

Pfizer is studying a potential treatment for multiple myeloma that uses a person’s immune system to fight off cancer cells.

We are conducting a series of clinical trials, called the MagnetisMM studies, to evaluate the safety and effectiveness of a study medicine called elranatamab (el-ruh-NAH-tuh-mab).

Elranatamab is given as a subcutaneous injection (a needle inserted under the skin in order to deliver the study medicine). It is thought to work by connecting certain immune system cells, known as T-cells, to myeloma cells. Connecting these cells activates the immune cells to kill the myeloma cells.

The MagnetisMM studies will have their own unique requirements for who may participate (eligibility criteria). The requirements may include your stage of multiple myeloma as well as any previous treatments you may have received.

If you or a loved one are considering participating in these studies, find more information in the clinical trials list below.

Refine your search

Find a multiple myeloma clinical trial

Refine your search by applying one of these filters.

Search
    Location
      Age (years)
      Sex

      Show filters

      Join PfizerLink — a clinical research registry

      Get notified about Pfizer clinical trials that may be right for you — now and over time.

      14 trials found

      All(14)
      Recruiting(13)
      Not yet recruiting(1)
      5 trials recruiting
      1 trial not yet recruiting
      MagnetisMM Clinical Trials

      These studies will evaluate the safety and effectiveness of a study medicine, called elranatamab, in people with multiple myeloma.

      Recruiting
      NCT06152575
      MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

      Multiple Myeloma

      Male or Female
      18+ years
      36study location(s)
      Recruiting
      NCT05317416
      Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

      Multiple Myeloma

      Male or Female
      18+ years
      264study location(s)
      Recruiting
      NCT05675449
      A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma

      Multiple Myeloma

      Male or Female
      18+ years
      62study location(s)
      Recruiting
      NCT06215118
      A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

      Multiple Myeloma

      Male or Female
      18+ years
      16study location(s)
      Recruiting
      NCT05090566
      MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

      Multiple Myeloma

      Male or Female
      18+ years
      84study location(s)
      Recruiting
      NCT06183489
      Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma

      Smoldering Multiple Myeloma

      Male or Female
      18+ years
      25study location(s)
      Recruiting
      NCT05623020
      A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135), Daratumumab, and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

      Multiple Myeloma

      Male or Female
      18+ years
      51study location(s)
      Recruiting
      NCT06138275
      Elranatamab in R/R Multiple Myeloma

      Refractory Multiple Myeloma, Relapse Multiple Myeloma, Multiple Myeloma

      Male or Female
      18+ years
      3study location(s)
      Recruiting
      NCT05896774
      A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China

      Non-Hodgkin Lymphoma, Multiple Myeloma

      Male or Female
      18+ years
      6study location(s)
      Recruiting
      NCT05020236
      MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

      Multiple Myeloma

      Male or Female
      18+ years
      52study location(s)

      Saved trials

      Saved trials

      You currently don’t have any saved trials. To save a trial, select the bookmark icon on the result listing.

      All(14)
      Recruiting(13)
      Not yet recruiting(1)

      Contact us

      For more information about participation in a Pfizer clinical trial, please email or call the Pfizer Clinical Trial Contact Center at 1-800-887-7002.


      About multiple myeloma

      Plasma cells are produced in healthy bone marrow. Plasma cells are a type of white blood cell that creates antibodies. These antibodies help your body kill germs and fight infection.

      Multiple myeloma is a type of blood cancer that forms in bone marrow. Multiple myeloma is when healthy plasma cells change and grow at a rapid pace. Abnormal (myeloma or cancer) plasma cells overcrowd and/or prevent the growth and creation of healthy plasma cells and other cells within the bone marrow.

      Like healthy plasma cells, some myeloma cells create antibodies. However, the antibodies don’t work properly, lowering your body’s ability to fight infection. Abnormal plasma cells also build up in the bones and organs, making it difficult for them to work properly, causing issues such as kidney problems.